sglt2 with glp 1 Effects of Pharmacologic Therapy for Diabetes Mellitus on The Endocrine System Cardiovascular benefits of SGLT2 inhibitors
Description
Unlike FDA-approved medications (e.g., Wegovy, Ozempic, Zepbound), compounded alternatives lack agency review for safety, quality, and efficacy
GLP1 agonists may risk muscle loss
Novo Nordisk is buying three Catalent facilities for $11bn in a bid to resolve supply issues holding back growth of Ozempic for diabetes and obesity therapy Wegovy.
Endocrinology Teams Top Recommendation
